GENMAB AS SP.ADR/1/10DK 1 Asset Resilience Ratio
GENMAB AS SP.ADR/1/10DK 1 asset resilience ratio. GENMAB AS SP.ADR/1/10DK 1 (GE91) has an Asset Resilience Ratio of 0.00% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See GE91 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of GENMAB AS SP.ADR/1/10DK 1 (2021–2025)
Asset resilience ratio of GENMAB AS SP.ADR/1/10DK 1 from 2021 to 2025. This chart shows how GENMAB AS SP.ADR/1/10DK 1's Asset Resilience Ratio has changed over time. Read debt load of GENMAB AS SP.ADR/1/10DK 1 for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down GENMAB AS SP.ADR/1/10DK 1's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see GENMAB AS SP.ADR/1/10DK 1 assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: GENMAB AS SP.ADR/1/10DK 1 maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
GENMAB AS SP.ADR/1/10DK 1 Industry Peers by Asset Resilience Ratio
Compare GENMAB AS SP.ADR/1/10DK 1's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
GENMAB AS SP.ADR/1/10DK 1 Asset Resilience Ratio by Year (2021–2025)
GENMAB AS SP.ADR/1/10DK 1 asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for GENMAB AS SP.ADR/1/10DK 1.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.00% | €0.00 ≈ $0.00 |
€12.87 Billion ≈ $15.05 Billion |
-- |
| 2024-12-31 | 24.54% | €1.57 Billion ≈ $1.83 Billion |
€6.39 Billion ≈ $7.47 Billion |
-13.06pp |
| 2023-12-31 | 37.60% | €1.97 Billion ≈ $2.30 Billion |
€5.24 Billion ≈ $6.13 Billion |
-3.67pp |
| 2022-12-31 | 41.27% | €1.79 Billion ≈ $2.09 Billion |
€4.33 Billion ≈ $5.07 Billion |
-0.88pp |
| 2021-12-31 | 42.15% | €1.58 Billion ≈ $1.85 Billion |
€3.75 Billion ≈ $4.38 Billion |
-- |
About GENMAB AS SP.ADR/1/10DK 1
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervi… Read more